SVFC : In-Human Clinical Studies
Osteoarthritis - phase 1 and 2a study
Dr. James Andrews & Prof. Saith Jazrawi (NYU), Dr. John Theodopolous (Mt. Sinai Toronto)
Focus: pain relief and cartilage regeneration using SVF via intravenous and injection. Randomized double-blind dose-controlled study to show safety and primary efficacy
Multiple Sclerosis - phase 1 and 2a study
Dr. Fred Lublim (Mt. Sinai, NY) recipient of largest-ever NIH grant ($40M) to find MS cure
In planning stages with Dr. Lublim for open label study of moderate to severe MS patients
Non-Healing Diabetic Ulcers - phase 1 and 2a study
Dr. Harold Brem (Winthrop Univ. Hospital NY), one of the foremost wound healing authorities
IntelliCell and Dr. Brem are developing a treatment methodology that may substantially alter
outcomes for subjects facing amputation as the only alternative
Oral Cavity Gum and Bone Regeneration - phase 1 and 2a study
Dr. Nicholas Toscano, Manhattan periodontics specialist
Study based on peer-reviewed SVF article showing restoration of gum tissue and bone mass
Dermal Regeneration - phase 1 and 2a study
Dr. Sydney Coleman (NY) and Dr. Peter Ashby (London), expert plastic surgeon in autologous cellular treatments
Study will focus on the regenerative capability of IntelliCells to address the aesthetic effects of SVF on wrinkles, lines, scarring, and burn conditions in the human skin
CORPORATE COLLABORATIONS
Millipore, a Division of Merck, Germany
accumulation of data and QA of specimens using flow cytometry
Numoda Corporation, Philadelphia
clinical trial accounting as our Clinical Research Organization
